STOCK TITAN

I-MAB American Depositary Shares - IMAB STOCK NEWS

Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.

I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.

The company’s pipeline includes several promising candidates:

  • Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
  • Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
  • Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
  • Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
  • Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).

I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.

Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.

For the latest updates and detailed information, visit the official website at I-Mab Biopharma.

Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced new collaborations with Immorna and neoX Biotech to enhance its oncology therapeutics pipeline. These partnerships focus on leveraging Immorna's self-replicating mRNA platform and neoX's AI-driven drug discovery technology for developing innovative anti-cancer antibody therapeutics. This initiative expands I-Mab's existing collaborations and strengthens its R&D capabilities. Both partnerships will involve undisclosed payments as part of the agreements, reflecting I-Mab's commitment to innovation in immuno-oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
-
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) has advanced its 4-1BB bispecific antibody portfolio, initiating a U.S. phase 1 clinical trial for TJ-CD4B/ABL111 in patients with advanced solid tumors, with the first dose administered on June 29, 2021. Chinese sites will join to expedite the study, targeting patients with gastric, esophageal, and pancreatic cancers. Additionally, preclinical results for TJ-L14B/ABL503 have been accepted for publication, showcasing superior anti-tumor activity. These developments promise to enhance immunotherapy strategies in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) has been recognized in the "Honored Companies" and "Best CFO" categories by Institutional Investor's 2021 All-Asia Executive Team survey, highlighting its commitment to innovation and financial management. Since its IPO in 2020, I-Mab has achieved key clinical milestones, maintaining over $6 billion in market capitalization. The company’s pipeline includes 16 assets, with 11 in clinical development. Recently, it raised $418 million in one of the largest PIPE financings and has been added to over 50 global indexes, underscoring its strong market presence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
Rhea-AI Summary

I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in the CMBI Healthcare Corporate Day virtual conference scheduled for July 7-9, 2021. Key executives, including Dr. Jingwu Zang and Dr. Joan Huaqiong Shen, will partake in one-on-one and small group meetings with attendees. I-Mab is focused on developing novel immuno-oncology therapeutics and has a robust pipeline of over 15 clinical and pre-clinical candidates. The company is progressing towards becoming a fully integrated global biopharmaceutical firm with substantial R&D and manufacturing capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none
-
Rhea-AI Summary

I-Mab (NASDAQ: IMAB) has received approval from the China National Medical Products Administration for its IND application to begin a phase 1b trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus. This multi-center study aims to assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics. Felzartamab targets dysregulated CD38-positive B cells, addressing a significant unmet need in SLE treatment. I-Mab is also pursuing registration trials for felzartamab in multiple myeloma across Greater China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
-
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced the appointment of Andrew Zhu, MD, PhD, to its Scientific Advisory Board. Dr. Zhu is a recognized expert in hepatobiliary cancers and has held key positions at Harvard Medical School and Massachusetts General Hospital. His experience is expected to enhance I-Mab's ongoing development of novel immuno-oncology therapies. This strategic move aligns with the company's mission to innovate in drug development and expand its clinical capabilities, potentially bolstering its competitive position in the biopharmaceutical industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
management
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced an investor call on June 7, 2021, to discuss in-depth clinical data from its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ®) for treating advanced cancers. Uliledlimab, a humanized antibody targeting CD73, aims to enhance anti-tumor immune responses and has shown promising preclinical results. The company is transitioning from clinical development to becoming a fully integrated global biopharmaceutical entity with a robust pipeline of over 15 drug candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
conferences clinical trial
-
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) has announced the election of Dr. Ruyi He and Professor Rong Shao to its board of directors, effective June 1, 2021. Dr. He, a former Chief Scientist at China's NMPA and current Chief Medical Officer at RemeGen Inc, brings extensive experience in drug evaluation and international policy implementation. Professor Shao is a leading expert in drug administration policies, holding roles at China Pharmaceutical University. Their appointments aim to enhance I-Mab’s strategic growth in the biopharmaceutical sector and bolster its transition into a fully integrated global company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
management
-
Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced its participation in several upcoming healthcare conferences in June 2021. Key events include the Jefferies Healthcare Conference on June 1 and various one-on-one meetings from June 2-4 and June 7-10. Notably, Dr. Joan Huaqiong Shen will present at the Haitong Annual Investor Conference on June 16. The company aims to advance its mission of developing innovative biologics in immuno-oncology, boasting a robust pipeline of over 15 clinical and pre-clinical candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.16%
Tags
none
Rhea-AI Summary

I-Mab announced promising results from a Phase 1 trial of uliledlimab, a novel CD73 antibody, in combination with atezolizumab for advanced cancer patients. The study reported favorable safety and tolerability, with no dose-limiting toxicities. Out of 13 efficacy-evaluable patients, 23% had complete or partial responses, while 46% showed stable disease. The U.S. trial data will be presented at ASCO 2021, where the abstract was selected as one of the Top 12 for poster discussion. I-Mab will host an investor call on June 7, 2021, to discuss the findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.17%
Tags

FAQ

What is the current stock price of I-MAB American Depositary Shares (IMAB)?

The current stock price of I-MAB American Depositary Shares (IMAB) is $0.923 as of December 20, 2024.

What is the market cap of I-MAB American Depositary Shares (IMAB)?

The market cap of I-MAB American Depositary Shares (IMAB) is approximately 76.3M.

What is I-Mab's core focus?

I-Mab focuses on discovering, developing, and commercializing novel and highly differentiated biologics to treat cancers and autoimmune disorders.

What are some key products in I-Mab's pipeline?

Key products include felzartamab, eftansomatropin, olamkicept, enoblituzumab, and efineptakin.

Where are I-Mab's main operations located?

I-Mab operates primarily from Rockville, Maryland, and San Diego, California.

What recent strategic move has I-Mab made?

I-Mab has divested its Chinese assets and operations to focus more on the U.S. and international markets.

What is felzartamab?

Felzartamab (TJ202) is a CD38 antibody in Phase III trials aimed at treating multiple myeloma and autoimmune diseases.

Who is I-Mab collaborating with on givastomig?

I-Mab is collaborating with Bristol Myers Squibb to study givastomig in combination with nivolumab and chemotherapy for advanced gastric and esophageal cancers.

How does I-Mab fund its operations and research?

I-Mab funds its operations through partnerships, strategic collaborations, and equity investments. Recent strategic divestitures also support its financial health.

What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?

The FDA's Breakthrough Therapy designation for felzartamab recognizes its potential to significantly improve treatment for primary membranous nephropathy and other immune-mediated diseases.

What is I-Mab's approach to drug development?

I-Mab employs Fast-to-Proof-of-Concept and Fast-to-Market strategies, leveraging internal R&D and global partnerships to expedite drug development.

How can investors stay updated on I-Mab's progress?

Investors can stay updated by visiting I-Mab's official website, following their social media channels, and accessing their annual reports and press releases.

I-MAB American Depositary Shares

Nasdaq:IMAB

IMAB Rankings

IMAB Stock Data

76.29M
62.31M
11.16%
30.88%
0.76%
Biotechnology
Healthcare
Link
United States of America
Rockville